HC Wainwright reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) in a report issued on Tuesday morning, Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock.
Enlivex Therapeutics Stock Down 3.3 %
Enlivex Therapeutics stock opened at $1.45 on Tuesday. Enlivex Therapeutics has a one year low of $1.15 and a one year high of $4.59. The business has a fifty day moving average price of $3.19 and a 200-day moving average price of $2.52.
Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last posted its quarterly earnings results on Friday, March 29th. The company reported ($0.48) EPS for the quarter. On average, research analysts predict that Enlivex Therapeutics will post -0.86 EPS for the current fiscal year.
Enlivex Therapeutics Company Profile
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.
Featured Articles
- Five stocks we like better than Enlivex Therapeutics
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Hasbro’s Management Made All the Right Calls This Quarter
- ETF Screener: Uses and Step-by-Step Guide
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How to invest in blue chip stocks
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
